Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
177
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 42 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 16, 2020 | Arsenic Trioxide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TRISENOX (DIN 02480387) under ATC L01XX27 ARSENIC TRIOXIDE. Indications are not published in the Drug Product… | DIN02480387 | withdrawnsource: Cancelled Post Marketsince Apr 18, 2023 | health-canada-dpd |
| Apr 15, 2020 | Mitomycin | FDA US | cancer not stated in this record | JELMYTO ® is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). JELMYTO is an alkylating… | ORIGNDA211728 | approved | openfda |
| Apr 10, 2020 | Selumetinib | FDA US | cancer not stated in this record | KOSELUGO is indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who… | ORIGNDA213756 | approved | openfda |
| Apr 8, 2020 | Encorafenib | FDA US | cancer not stated in this record | Efficacy supplement 2020-04-08 (see label) | SUPPLNDA210496 | approved | openfda |
| Apr 3, 2020 | Cinacalcet | EMA EU | cancer not stated in this record | Secondary hyperparathyroidism AdultsTreatment of secondary hyperparathyroidism (HPT) in adult patients with end-stage renal disease (ESRD)… | centralisedEMEA/H/C/005236 | approved | ema |
| Apr 1, 2020 | Arsenic Trioxide | EMA EU | Acute Promyelocytic Leukemia | Arsenic trioxide Mylan is indicated for induction of remission, and consolidation in adult patients with:- Newly diagnosed low to… | centralisedEMEA/H/C/005235 | withdrawnsince Apr 14, 2025 | ema |
| Apr 1, 2020 | Rituximab | EMA EU | cancer not stated in this record | Ruxience is indicated in adults for the following indications: Non?Hodgkin’s lymphoma (NHL) Ruxience is indicated for the treatment of… | centralisedEMEA/H/C/004696 | approved | ema |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 30, 2020 | Abemaciclib | FDA US | cancer not stated in this record | Efficacy supplement 2020-03-30 (see label) | SUPPLNDA208716 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 31, 2020 | Arsenic Trioxide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ARSENIC TRIOXIDE SOLUTION FOR INJECTION (DIN 02487357) under ATC L01XX27 ARSENIC TRIOXIDE. Indications are not… | DIN |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| Mar 27, 2020 | Peginterferon Beta-1a | FDA US | cancer not stated in this record | Efficacy supplement 2020-03-27 (see label) | SUPPLBLA125499 | approved | openfda |
| Mar 27, 2020 | Obinutuzumab | FDA US | cancer not stated in this record | Efficacy supplement 2020-03-27 (see label) | SUPPLBLA125486 | approved | openfda |
| Mar 27, 2020 | Interferon Beta-1a | FDA US | cancer not stated in this record | Efficacy supplement 2020-03-27 (see label) | SUPPLBLA103628 | approved | openfda |
| Mar 27, 2020 | Azacitidine | EMA EU | cancer not stated in this record | Azacitidine Mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT)… | centralisedEMEA/H/C/004984 | approved | ema |
| Mar 27, 2020 | Darolutamide | EMA EU | Nonmetastatic Castration-Resistant Prostate Carcinoma | NUBEQA is indicated for the treatment of adult men with non‑metastatic castration resistant prostate cancer (nmCRPC) who are at high risk… | centralisedEMEA/H/C/004790 | approved | ema |
| Mar 27, 2020 | Durvalumab | FDA US | cancer not stated in this record | Efficacy supplement 2020-03-27 (see label) | SUPPLBLA761069 | approved | openfda |
| Mar 24, 2020 | Azacitidine | EMA EU | cancer not stated in this record | Azacitidine betapharm is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation… | centralisedEMEA/H/C/005075 | approved | ema |
| Mar 24, 2020 | Darolutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as NUBEQA (DIN 02496348) under ATC L02BB06 DAROLUTAMIDE. Indications are not published in the Drug Product Database —… | DIN02496348 | approvedsource: Marketed | health-canada-dpd |
| Mar 12, 2020 | Thyrotropin Alfa | FDA US | cancer not stated in this record | Efficacy supplement 2020-03-12 (see label) | SUPPLBLA020898 | approved | openfda |
| Mar 11, 2020 | Gemtuzumab Ozogamicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as MYLOTARG (DIN 02494388) under ATC L01FX02 GEMTUZUMAB OZOGAMICIN. Indications are not published in the Drug Product… | DIN02494388 | approvedsource: Marketed | health-canada-dpd |
| Mar 10, 2020 | Entrectinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ROZLYTREK (DIN 02495007) under ATC L01EX14 ENTRECTINIB. Indications are not published in the Drug Product Database —… | DIN02495007 | approvedsource: Marketed | health-canada-dpd |
| Mar 10, 2020 | Nivolumab | FDA US | cancer not stated in this record | Efficacy supplement 2020-03-10 (see label) | SUPPLBLA125554 | approved | openfda |
| Mar 10, 2020 | Ipilimumab | FDA US | cancer not stated in this record | Efficacy supplement 2020-03-10 (see label) | SUPPLBLA125377 | approved | openfda |
| Mar 9, 2020 | Talazoparib | FDA US | cancer not stated in this record | Efficacy supplement 2020-03-09 (see label) | SUPPLNDA211651 | approved | openfda |
| Mar 9, 2020 | Nintedanib | FDA US | cancer not stated in this record | Efficacy supplement 2020-03-09 (see label) | SUPPLNDA205832 | approved | openfda |
| Mar 4, 2020 | Entrectinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ROZLYTREK (DIN 02495015) under ATC L01EX14 ENTRECTINIB. Indications are not published in the Drug Product Database —… | DIN02495015 | approvedsource: Marketed | health-canada-dpd |
| Mar 2, 2020 | Isatuximab | FDA US | Multiple Myeloma | SARCLISA is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who… | ORIGBLA761113 | approved | openfda |
| Feb 25, 2020 | Neratinib | FDA US | cancer not stated in this record | Efficacy supplement 2020-02-25 (see label) | SUPPLNDA208051 | approved | openfda |
| Feb 13, 2020 | Azacitidine | EMA EU | cancer not stated in this record | Azacitidine Accord is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation… | centralisedEMEA/H/C/005147 | approved | ema |
| Feb 8, 2020 | Pemetrexed | FDA US | Pleural Malignant Mesothelioma | in combination with cisplatin for the initial treatment, of patients with malignant pleural mesothelioma whose disease is unresectable or… | ORIGNDA209472 | approved | openfda |
| Feb 8, 2020 | Pemetrexed | FDA US | Lung Non-Small Cell Carcinoma | Limitations of Use : PEMFEXY is not indicated for the treatment of patients with squamous cell non-small cell lung cancer. | ORIGNDA209472 | approved | openfda |
| Feb 8, 2020 | Pemetrexed | FDA US | Lung Non-Squamous Non-Small Cell Carcinoma | as a single agent for the treatment of patients with recurrent, metastatic non-squamous NSCLC after prior chemotherapy. | ORIGNDA209472 | approved | openfda |
| Feb 8, 2020 | Pemetrexed | FDA US | Lung Non-Squamous Non-Small Cell Carcinoma | as a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous NSCLC whose disease has not… | ORIGNDA209472 | approved | openfda |
| Feb 8, 2020 | Pemetrexed | FDA US | Lung Non-Squamous Non-Small Cell Carcinoma | in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous, non-small cell lung… | ORIGNDA209472 | approved | openfda |
| Feb 8, 2020 | Pemetrexed | FDA US | Lung Non-Squamous Non-Small Cell Carcinoma | in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with… | ORIGNDA209472 | approved | openfda |
| Feb 7, 2020 | Pegfilgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as FULPHILA (DIN 02484153) under ATC L03AA13 PEGFILGRASTIM. Indications are not published in the Drug Product Database —… | DIN02484153 | approvedsource: Marketed | health-canada-dpd |
| Feb 3, 2020 | Gilteritinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as XOSPATA (DIN 02495058) under ATC L01EX13 GILTERITINIB. Indications are not published in the Drug Product Database —… | DIN02495058 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jan 23, 2020 | Tazemetostat | FDA US | cancer not stated in this record | These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for… | ORIGNDA211723 | approved | openfda |
| Jan 23, 2020 | Tazemetostat | FDA US | Follicular Lymphoma | Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. | ORIGNDA211723 | approved | openfda |
| Jan 23, 2020 | Tazemetostat | FDA US | Follicular Lymphoma | Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an… | ORIGNDA211723 | approved | openfda |
| Jan 23, 2020 | Tazemetostat | FDA US | Epithelioid Sarcoma | Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete… | ORIGNDA211723 | approved | openfda |
| Jan 21, 2020 | Teprotumumab | FDA US | cancer not stated in this record | TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration. TEPEZZA is an… | ORIGBLA761143 | approved | openfda |
| Jan 16, 2020 | Polatuzumab Vedotin | EMA EU | Diffuse Large B-Cell Lymphoma | Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse… | centralisedEMEA/H/C/004870 | approved | ema |
| Jan 16, 2020 | Pertuzumab | FDA US | cancer not stated in this record | Efficacy supplement 2020-01-16 (see label) | SUPPLBLA125409 | approved | openfda |
| Jan 15, 2020 | Pasireotide | FDA US | cancer not stated in this record | Efficacy supplement 2020-01-15 (see label) | SUPPLNDA200677 | approved | openfda |
| Jan 9, 2020 | Niraparib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZEJULA (DIN 02489783) under ATC L01XK02 NIRAPARIB. Indications are not published in the Drug Product Database — see… | DIN02489783 | withdrawnsource: Dormantsince Oct 26, 2024 | health-canada-dpd |
| Jan 9, 2020 | Avapritinib | FDA US | cancer not stated in this record | Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth… | ORIGNDA212608 | approved | openfda |
| Jan 8, 2020 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2020-01-08 (see label) | SUPPLBLA125514 | approved | openfda |
| Jan 6, 2020 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-DASATINIB (DIN 02481502) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02481502 | approvedsource: Marketed | health-canada-dpd |
| Jan 6, 2020 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-DASATINIB (DIN 02481499) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02481499 | approvedsource: Marketed | health-canada-dpd |